WVE-006

DRUG3 trials

Sponsors

Wave Life Sciences Ireland Limited, Wave Life Sciences Ltd.

Conditions

Alpha-1 Antitrypsin DeficiencyAlpha-1 Antitrypsin Deficiency (AATD)Alpha-1 antitrypsin deficiency (AATD)

Phase 1

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)

CompletedNCT06186492

Wave Life Sciences Ltd.Alpha-1 Antitrypsin Deficiency (AATD)

Start: 2023-11-14End: 2025-02-13Updated: 2026-03-23

A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD

Active, not recruitingNCT06405633

Wave Life Sciences Ltd.Alpha-1 Antitrypsin Deficiency

Start: 2024-07-19End: 2026-09-01Target: 24Updated: 2026-04-14

A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants with AATD Pi*ZZ on WVE-006 (RestorAATion-2)

RecruitingCTIS2024-511981-36-00

Wave Life Sciences Ireland LimitedAlpha-1 antitrypsin deficiency (AATD)

Start: 2025-01-06Target: 7Updated: 2025-10-10